Hemab reports Q1 net loss $22.7M; completes $346.7M IPO, gets BTD for sutacimig

Hemab Therapeutics Holdings, Inc.

Net loss Q1 2026: $22.7M ($23.98/share) vs $15.3M ($16.18/share) YoY.
Cash $163.5M at March 31; with $317.2M net IPO proceeds, runway into 2029.
Completed IPO in May 2026: 19.26M shares at $18.00, raising $346.7M gross; now listed on Nasdaq under COAG.
FDA granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia in March 2026.
Preparing Phase 3 pivotal trial for sutacimig in GT expected H2 2026; data from Factor VII and VWD trials in late 2026/early 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Hemab Therapeutics Holdings, Inc. reported the first quarter ended March 31, 2026 results: net income $22.7 million, or $23.98 per share, EPS $23.98 per share.

Period: the first quarter ended March 31, 2026
Net income: $22.7 million, or $23.98 per share
EPS: $23.98 per share
Result: reported results

Exact text from the filing

Hemab Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.

View on SEC.gov

169 earnings releases filed in the last 30 days. Browse all earnings releases →

Hemab Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-233375

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.